A randomized trial Comparing the Effects of Febuxostat and Allopurinol on renal function and left ventricular hypertrophy for chronic heart failure patient with hyperuricemia complicated by chronic kidney disease stage G3-G4.
Not Applicable
- Conditions
- Chronic heart failure patients with hyperuricemia
- Registration Number
- JPRN-UMIN000014309
- Lead Sponsor
- Asahikawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have allergy to febuxostat or allopurinol. 2) Patients who take mercaptopurine or azathioprine. 3) Nephrotic syndrome,dialysis patients,renal transplant or on other serious disease 4) Patients with AST or ALT level over than the twice the facilitie standard value. 5) Patients who have complication of malignant tumor. 6) Pregnant, possibly pregnant, brest-feeding, or expecting to conceive. 7) Written informed consent by his/her own will not. 8) Patients who are judged as inadequate to participate the study by the their doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eGFR slope (change of eGFR from the baseline to 52 weeks)
- Secondary Outcome Measures
Name Time Method 1) Cardiac function indexes on echocardiography (LVEF, LVMI, LVEDV, LVESV, %FS, RWT) and (E, A, DT, E/e') 2) The amount of change of serum uric acid value and BNP 3) The amount of change of urine protein,urinecreatinine, the albumin urine/creatinine ratio and the albumin urine 4) The amount of change of eGFR and cystatin C 5) The amount of change of L-FABP and o-LDL 6) The amount of change of hsCRP 7) The amount of change of EPA/AA 8) Achievement quotient of serum uric level urine 6.0mg/dl 9) Incidence of adverse event